The EU is investing in the development of personalised medicine, which allows doctors to offer preventative treatments for cancer and heart disease. Most commonly used to treat cancer, personalised medicine can offer patients the best possible treatment by focusing on the individual genetic and biological make-up of their tumours. Thanks to advances in research, personalised medicine could be made available to more patients, and scientists are optimistic about its future. If traditional treatments are ineffective, or the cancer is recurrent, patients can undergo tests to determine the specific molecular anomalies in their tumours, and how bestto block theirenzyme activity. Doctors can then target these anomalies, which may occur in multiple cancers, and are thus able to prescribe medication to treat several tumours simultaneously. "Personalised medicine works by focusing on the genetic make-up of the tumour, rather than the patient," Agns Buzyn, president of the French National Cancer Institute (INCA), explained during a Medef Summer University workshop. External factors such as environment and lifestyle are also taken into account, as they can influence a patient's illness andthe effectiveness of its treatment. Heart disease risk-assessment Personalised medicine can also be used to treat heart disease. Risk assessment can greatly improve the effectiveness … Continue reading →

IRVINE, CA and ANNAPOLIS JUNCTION, MD (PRWEB) September 04, 2014 Proove Biosciences, the commercial and research leader in personalized medicine, will be attending the 21st Annual Napa Pain Conference, September 5th-7th, at the Meritage Conference Center. Proove will specifically be presenting research conducted through their proprietary PILL II Study. The PILL II study examined the prevalence of genetic variations in a population of chronic pain patients who were taking prescription opioids. Proove researchers found that there is in fact a greater prevalence of these genetic variations in the study group vs. the control population. The Napa Pain Conference is a leading CME pain management conference that traditionally presents new data and best practices in pain therapies. The conference is designed to provide significant educational opportunity to everyone, regardless of position, or role in the pain management and pain treatment industry. Proove Biosciences genetic testing has allowed pain management physicians to better assess their patients needs by analyzing how they will react to specific treatments, and help physicians decide if there are better alternatives to consider, stated Brian Meshkin, CEO of Proove Biosciences. The nationally acclaimed annual conference is the premier event for the study of pain diagnosis and treatment. Regarding … Continue reading →

It is 14 years since Tony Blair and Bill Clinton invited the world's media to the White House for an announcement that would have seemed like science fiction just a few years earlier: the entire human genome - the genetic blueprint of human beings - had been mapped for the first time. Looking somewhat awestruck, the prime minister and the president promised their press conference would pave the way for 'a new era of genetic medicine'. This was not a hollow pledge, but genomics is only now beginning to fulfil its potential. How can investors gain the diversification that is important in all facets of investing in biotechnology through genomics? Read more: Six stocks and funds to give investors exposure to genomics. The two world leaders were right in their view that genomics would prove to be a disruptive technology (not that they would have used the term). But just as it took the mass-produced Ford Model T to translate the invention of the automobile into a technology that changed the world, so the first map of the human genome was not quite the game changer Blair and Clinton anticipated. 'The real catalyst for the take-off of genomics has been … Continue reading →